Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Randomized Cross-Over, 2-Period, 2-Way Interaction Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-State in Healthy Subjects.

Next Previous
X
Search
Trial Profile

A Phase I, Open-Label, Randomized Cross-Over, 2-Period, 2-Way Interaction Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-State in Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2012

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etravirine (Primary) ; Lopinavir/ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Janssen R&D Ireland

    • Most Recent Events

    • 01 May 2012 Results published in the Journal of Clinical Pharmacology.
    • 11 Nov 2009 Results were presented at EACS 2009.
    • 09 Oct 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top